EGFR and neuroblastoma: Morris et al. reported that combining IR and an intratumoral IL2-linked tumor-associated antigen-specific antibody (anti-GD2 Hu14.18K322A or anti-EGFR cetuximab) in mouse models of melanoma, neuroblastoma, and head and neck squamous cell carcinoma eradicated both large tumors and metastases and elicited T cell immune responses against primary tumors that can be further leveraged by anti-CTLA-4 T cell checkpoint blockade to reduce lung metastasis [48, 49].